 |  |
- Best-in-class, highly selective separations technology for the radiopharmaceuticals industry
- Exhibitor at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany 20-23 October 2024 at Booth S14 (Exhibition Hall 3)
- Over 36 years of experience with first generation flowsheets for highly selective separation of radium (Ra), lead (Pb), thorium (Th), actinium (Ac), bismuth (Bi), copper (Cu) and others
- Highly selective purification of Ra-228 incorporated in Pb-212 flowsheet used by OranoMed to produce AlphaMedix for treatment of neuroendocrine tumors (NETs)
- Second generation flowsheets to drive increased availability and scaleability of critical radioisotope supply, including Pb-212, Ac-225, Ra-226, Th-227, Bi-213 and others
- Highly selective recovery of radium to nanogram per liter concentrations from brines, mining streams and nuclear wastes
- Waste minimization
- Industrial manufacturing capability
RadSep's proprietary Molecular Recognition Technology™ (MRT™) introduces a comprehensive approach to separating upstream radioisotopes used in the production of feedstocks, as well as downstream radioisotopes used directly in the manufacture of drug products for radioligand therapies (RLTs). When embedded in a production process, including in a Current Good Manufacturing Practice (cGMP) environment, MRT™ enables highly selective, single-step separation of critical radioisotopes, benefiting the supply chain and alleviating shortages caused by sub-optimal separation processes, such as ion exchange resins. MRT™ can thus be used in the industrial setting in order to conserve and recycle critical radioisotopes such as Ra-226.